

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jul 2026

Evaluation of the effect of vitamin D supplementation on insulin resistance, lipid profile, thyroid function indices and body composition in overweight and obese patients with hypothyroidism and glucose intolerance

Protocol summary

Study aim

Determining the effect of vitamin D supplementation on insulin resistance, lipid profile, thyroid function indices, and body composition in overweight and obese patients with hypothyroidism and glucose intolerance

Design

A double-blind randomized controlled clinical at phase 3, in which 50 participants using block randomization will be randomly assigned to two groups. Participants in the control group receive vitamin D daily for 12 weeks and the control group uses a placebo in the same order.

Settings and conduct

Fifty patients who were referred to Shahid Mofteh Educational and Medical Polyclinic in Yasouj will be included in the study. After being informed and signing the informed consent form, the demographic characteristics of participants will be recorded. Participants will randomly be allocated to either intervention or control group which are named as A or B, in order to blind both investigators and participants and use relevant treatment based on their allocated groups. Anthropometrics will be assessed at the beginning and after the intervention. Blood samples will also be taken before and after the intervention to measure insulin resistance, thyroid function, and lipid profile.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Overweight and obese individuals aged 20 to 75 years with hypothyroidism and glucose intolerance; and Serum vitamin D less than 30 ng/ml; Exclusion criteria: cancer, kidney, liver, cardiovascular, bone and endocrine disorders other than hypothyroidism and glucose intolerance; taking multivitamins-minerals; being pregnant or in breastfeeding duration

Intervention groups

There are two groups in this study: Intervention group: Receive 4000 IU vitamin D3 supplement daily for 12

weeks. Control group: Receive placebo daily for 12 weeks.

Main outcome variables

Insulin resistance; lipid profile; thyroid function indices, and body composition

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210630051751N1**

Registration date: **2021-10-11, 1400/07/19**

Registration timing: **prospective**

Last update: **2021-10-11, 1400/07/19**

Update count: **0**

Registration date

2021-10-11, 1400/07/19

Registrant information

Name

Nasrin Dahesh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8670 5503

Email address

n.dahesh1371@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-10-12, 1400/07/20

Expected recruitment end date

2022-01-20, 1400/10/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of vitamin D supplementation on insulin resistance, lipid profile, thyroid function indices and body composition in overweight and obese patients with hypothyroidism and glucose intolerance

Public title

Evaluation of the effect of vitamin D supplementation on insulin resistance, lipid profile, thyroid function indices and body composition in overweight and obese patients with hypothyroidism and glucose intolerance

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Individuals between 20 and 75 years old. Overweight or obese individuals with a body mass index above 25. Individuals Suffering from hypothyroidism with TSH levels higher than 7 microIU/ml. Individuals with impaired glucose tolerance with fasting plasma glucose levels above 100 mg/dL or 2-hour plasma glucose above 140 mg / dL. Individuals with serum 25-hydroxyvitamin D3 concentration is less than 30 ng/ml.

Exclusion criteria:

Individuals with cancer, kidney, liver, cardiovascular, bone, and endocrine diseases other than hypothyroidism and glucose intolerance disorders. Individuals taking drugs related to diseases such as cancer, kidney, liver, heart, and drugs that affect bone metabolism (estrogen, selective estrogen receptor modulator, bisphosphonate, vitamin D, or calcium). Individuals consuming multivitamins-minerals. Pregnant and lactating women.

AgeFrom **20 years** old to **75 years** old**Gender**

Both

Phase

3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor
- Data analyser

Sample sizeTarget sample size: **50****Randomization (investigator's opinion)**

Randomized

Randomization description

Randomization is done using the block randomization method (1: 1 ratio for intervention and control groups). In this method, blocks of two with a rotation will be created. Then one of these blocks is randomly selected to

determine the allocated group for the first and second participants. After that, this random block selection process is repeated to determine the sequence of random allocation until the end of the desired sample size. After determining the randomized sequence, these sequences will be placed in sealed envelopes. The process will be done by an out-of-study person familiar with randomization. Then, when a participant enters the study, an envelope will be opened according to the order and the participant's group will be identified.

Blinding (investigator's opinion)

Double blinded

Blinding description

The capsules for the intervention and control group are the same in terms of appearance characteristics such as color, shape, and size. Capsules are named according to the intervention groups with the same names as A and B by someone outside the study who is not aware of the objectives and method of study. Therefore, both the research team and the participant are blinded to receiving the supplement or placebo.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Shiraz University of Medical Sciences

Street address

Shiraz - Zand Alley - Central building of Fars University of Medical Sciences and Health Services

City

Shiraz

Province

Fars

Postal code

۷۱۳۴۸۱۴۳۳۶

Approval date

2021-06-19, 1400/03/29

Ethics committee reference number

IR.SUMS.REC.1400.261

Health conditions studied**1****Description of health condition studied**

Hypothyroidism

ICD-10 code

E03

ICD-10 code description

Other hypothyroidism

2

Description of health condition studied

Impaired glucose tolerance

ICD-10 code

R73.02

ICD-10 code description

Impaired glucose tolerance (oral)

3

Description of health condition studied

Overweight and obesity

ICD-10 code

E66

ICD-10 code description

Overweight and obesity

Primary outcomes

1

Description

Insulin resistance: A disorder of glucose homeostasis that is defined as a decrease in the sensitivity of adipose tissue, liver, liver, and other body tissues to insulin, despite normal or elevated levels of insulin in the blood.

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Using the formula HOMA-IR: [Fasting insulin(mIU/L) × fasting glucose(mg/dL)]/405

Secondary outcomes

1

Description

Weight: Weight of a person with light minimum possible clothes and without shoes with an accuracy of 100 grams

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Scales

2

Description

BMI: [Weight(kg)]/[height (cm) * height (cm)]

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Formula

3

Description

Waist Circumference: the smallest circumference of waist in centimeters

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Tape measure

4

Description

Serum TSH

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

ELISA

5

Description

Serum T3

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

ELISA

6

Description

Serum T4

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Eliza

7

Description

Fasting serum insulin

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

8

Description

Fasting serum glucose

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

9

Description

HbA1c

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

10

Description

Serum LDL-c

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

11

Description

Serum HDL-c

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

12

Description

Serum total cholesterol

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

13

Description

Serum triglycerides

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Spectrophotometer

14

Description

Body Fat

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Body Analyzer

15

Description

P.B.F (Percent Body Fat)

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Body Analyzer

16

Description

Visceral fat

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Body Analyzer

17

Description

Subcutaneous fat

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Body Analyzer

18

Description

Waist to Hip Ratio

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Body Analyzer

19

Description

T.E.E (Total Energy Expenditure)

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

Body Analyzer

20

Description

Serum 25- Hydroxy vitamin D

Timepoint

At the beginning of the study (before the intervention) and 12 weeks later at the end of the intervention

Method of measurement

ELISA

Intervention groups

1

Description

Intervention group: For 12 weeks, receive vitamin D3 supplement daily (containing 4000 IU of vitamin D3, produced by Zahravi Pharmaceutical Company).

Category

Treatment - Drugs

2

Description

For 12 weeks, they receive a placebo (produced by Zahravi Pharmaceutical Company, which is similar in appearance characteristics to the supplement used in the intervention group).

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Mofteh Shahid Mofteh specialized and sub-specialized polyclinic in Yasuj

Full name of responsible person

Dr. Sajjad Hassanzadeh

Street address

Kohkilouyeh and Boyerahmad - Yasuj: 15th Golestan St. 15th

City

yasuj

Province

Kohgilouyeh-va-Boyerahmad

Postal code

7591974638

Phone

+98 74 1222 3299

Email

n.daresh1371@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Abbas Rezaeianzadeh

Street address

Shiraz - Zand Alley - Central building of Fars University of Medical Sciences and Health Services

City

Shiraz

Province

Fars

Postal code

۷۱۳۴۸۱۴۳۳۶

Phone

+98 71 3212 2430

Email

vcrdep@sums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Mohammad Hassan Eftekhari

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Faculty of Nutrition and Food Sciences, Zahra Alley, Shiraz

City

Shiraz

Province

Fars

Postal code

111 - 71645

Phone

00988-7251001 3- 071

Email

H_eftekhari@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Mohammad Hassan Eftekhari

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Faculty of Nutrition and Food Sciences, Zahra Alley, Shiraz

City

Shiraz

Province

Fars

Postal code

111 - 71645

Phone

00988-7251001 3- 071

Email

H_eftehkari@yahoo.com

009874332298

Email

n.dahesh1371@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Nasrin Dahesh

Position

students

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

No. 2, Saadi Alley, Terminal St., Yasuj

City

Yasuj

Province

Kohgiluyeh-va-Boyer-Ahmad

Postal code

7591974638

Phone

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available